**A Clinical Diagnostic Algorithm for Early Onset Cerebellar Ataxia**

R Brandsma1, CC Verschuuren-Bemelmans2, D Amrom3, N Barisic4, P Baxter5, E Bertini6, L Blumkin7, V Brankovic-Sreckovic8, OF Brouwer1, K Bürk9, CE Catsman-Berrevoets10, D Craiu11, IFM de Coo12, J Gburek13, C Kennedy14, TJ de Koning2,15, HPH Kremer1, R Kumar16 A Macaya17, A Micalizzi18, M Mirabelli-Badenier19, A Nemeth20, S Nuovo21,22, B Poll-The23, T Lerman-Sagie7, M Steinlin24, M Synofzik25,26, MAJ Tijssen1, G Vasco27, MAAP Willemsen28, G Zanni6, EM Valente21,29, E Boltshauser30 and DA Sival15

1Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

2Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

3Department of Neurology Unit, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels,  
 Belgium

4Department of Pediatrics, Clinical Medical Centre Zagreb, University of Zagreb Medical School, Croatia

5Department of Paediatric Neurology, Sheffield Children's Hospital, UK

6Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesu’ Children’s Research Hospital, Rome, Italy

7Pediatric Neurology Unit, Wolfson Medical Center, Holon and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

8Clinic for Child Neurologyand psychiatry, Medical Faculty, University of Belgrade, Belgrade, Serbia

9Paracelsus-Elena-Klinik Kassel, and University of Marburg, Germany

10Department of Pediatric Neurology, Erasmus University Hospital / Sophia Children's Hospital, Rotterdam, The Netherlands

11Carol Davila University of Medicine Bucharest, Department of Clinical Neurosciences, Pediatric Neurology II Discipline,  
 Alexandru Obregia Hospital, Bucharest, Romania

12Department of Genetics and Cell Biology, University of Maastricht, Maastricht, the Netherlands

13Centre for Paediatrics and Adolescent Medicine, Hannover Medical School, Hannover, Germany

14Clinical Neurosciences, Faculty of Medicine, University of Southampton, UK

15Department of Paediatric Neurology, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen,  
 Groningen, the Netherlands

16Department of Pediatric Neurology, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK

17Grup de Recerca en Neurologia Pediàtrica, Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona, Secció de  
 Neurologia Pediàtrica, Hospital Universitari Vall d'Hebron, 08002 Barcelona, Spain

18Laboratory of Medical Genetics, Bambino Gesu Children’s Hospital, Rome, Italy

19DINOGMI Department-University of Genoa / Unit of Child Neuropsychiatry, G. Gaslini Institute, Genoa, Italy

20Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; Oxford Centre for Genomic  
 Medicine, Oxford University Hospitals NHS Trust, Oxford, United Kingdom

21Neurogenetics Unit, IRCCS Santa Lucia Foundation, Rome, Italy

22Department of Medicine and Surgery, University of Salerno, Salerno, Italy

23Department of Pediatric Neurology, Emma Children’s Hospital, Academic Medical Centre (AMC), University of Amsterdam,  
 the Netherlands

24Division of Neuropediatrics, Development and Rehabilitation, University Children's Hospital Bern, Inselspital, Bern University  
 Hospital, University of Bern, Switzerland

25Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University  
 of Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany

26German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany

27Division of Neurorehabilitation, Bambino Gesu’ Children’s Research Hospital, Rome, Italy

28Department of Pediatric Neurology, Radboud University Medical Center / Amalia Children’s Hospital, Nijmegen, the  
 Netherlands

29Department of Molecular Medicine, University of Pavia, Pavia, Italy

30Department of Pediatric Neurology, University Children’s hospital, Zürich, Switzerland

**Correspondence to:**

D.A. Sival, MD PhD

Department of Paediatrics Neurology, Beatrix Children’s Hospital,

University Medical Center Groningen

PO Box 30.001, 9700RB Groningen, The Netherlands

Email: d.a.sival@umcg.nl

Phone: +31-50-3611085 / Fax: +31-50-3611787

**Word count: 4008**

**Abstract**

Early onset cerebellar Ataxia (EOAc) comprises a large group of rare heterogeneous disorders. Determination of the underlying etiology can be difficult given the broad differential diagnosis and the complexity of the genotype-phenotype relationships. This may change the diagnostic work-up into a time-consuming, costly and not always rewarding task. In this overview, the Childhood Ataxia and Cerebellar Group of the European Pediatric Neurology Society (CACG-EPNS) presents a diagnostic algorithm for EOAc patients. In seven consecutive steps, the algorithm leads the clinician through the diagnostic process, including EOA identification, application of the Inventory of Non-Ataxic Signs (INAS), consideration of the family history, neuro-imaging, laboratory investigations, genetic testing by array CGH and Next Generation Sequencing (NGS). In children with EOAc, this algorithm is intended to contribute to the diagnostic process and to allow uniform data entry in EOAc databases.

**Key words:** Early Onset Ataxia, Child, Algorithm, NGS techniques, Cerebellum, Diagnosis

**1. Introduction**

Early onset cerebellar ataxia (EOAc) comprises a large group of patients with rare disorders, manifesting symptomatic cerebellar ataxia before the age of 25 years. The estimated prevalence of EOA is 14.6 per 100.000 individuals.(1–4). Inheritance patterns can be classified as: autosomal recessive (most frequently), mitochondrial or autosomal dominant. In the latter, a strong family history (sometimes with misdiagnosed family members) is frequently present or the mutation appears *de novo*. In contrast with adult onset ataxia, EOAc often presents with a wide variety of genotypes. This can be attributed to the neurological and non-neurological co-morbid features (5,6), and to the variable disease course, which may range from stable- to relentlessly progressive. Another aspect is that the initially dominating ataxic movement disorder phenotype may change over time. This is illustrated by young children suffering from the North Sea Progressive Myoclonus Epilepsy syndrome (caused by *GOSR2* mutation), who initially present with ataxia as one of the major symptoms at preschool age, which is progressively over-taken by myoclonus from about five years of age onwards.(7). Finally, it is important to realize that the heterogeneity of the EOAc phenotypes also reflects the heterogeneity of the underlying diseases. For instance, mitochondrial disorders involving both nuclear and mitochondrial genotypes can induce a large variety in clinical multisystem phenotypes, with proneness for ataxic features due to the energy demand of the cerebellar Purkinje cells.(8) To summarize, in children with EOAc, there is a large variety in genotypes with a heterogeneous phenotypic presentation. This can make the diagnostic work-up a challenging, time-consuming and expensive task, not only for the clinician but also for the children and their parents.

Over the past years, the availability of innovative Next Generation Sequencing (NGS) techniques (9–11) has enormously increased the diagnostic yield in pediatric neurologic disorders, such as epilepsy and childhood dystonia.(10,12,13) To optimize the diagnostic process in children with EOAc, the Childhood Ataxia and Cerebellar Group of the European Paediatric Neurology Society (CACG-EPNS) has developed this diagnostic algorithm, based on the available literature as well as on expert opinions, expressed during the CACG-EPNS meetings over the last decade. After evaluation of the disease history, the present EOA algorithm will lead the clinician through the diagnostic process in seven consecutive steps (figure 1).

**2. Clinical evaluation of the disease history**

**2.1. Step I: The clinical assessment of ataxia**

The concept of “Early-Onset Ataxia” (EOA) refers to a heterogeneous group of diseases, mostly of genetic and/or metabolic origin, initiating before 25 years of age. In this algorithm, we focus on the detection of EOA by underlying cerebellar etiology (EOAc). Cerebellar ataxia is characterized by the loss of smooth goal directed and intended movements, after exclusion of other causes such as weakness and/or sensory disturbances.(14) In the newborn with absent voluntary movements, disturbed cerebellar function is often expressed by a stable or (slowly) progressive disease presentation with hypotonia, hypo-activity and oculomotor abnormalities.(15) This is illustrated by neonates with pontocerebellar hypoplasia type 2 who present with low muscle tone and jitteriness. Apart from uncoordinated sucking and swallowing behaviour, clear ataxic features are mostly invisible due to pronounced hypo-activity.(16) After the neonatal period, when the child starts to develop voluntary goal directed movements, ataxic features become more clearly recognizable by coordination impairment. These cerebellar ataxic features are characterized by an impairment of smooth, goal directed movements and reduced fine-tuning in speed, force and direction. There is often a delay in motor milestones, and sometimes also in cognition and speech. (6,14,17,18)   
In general, genetic causes of ataxia are associated with an insidious disease onset, whereas acquired ataxias are associated with a (sub-) acute disease onset. There are, however, exceptions to these patterns, as demonstrated by the genetically inheritable disorders causing paroxysmal episodic ataxia with an acute on- and offset. A clinical video-recording of the paroxysmal event may be indicative. When suspected, one should always look for potential triggers, such as physical and emotional stress. These episodic EOAc phenotypes may prompt genetic testing with a specific “NGS panel” for paroxysmal disorders. (see Table I).

Specific cerebellar domains are associated with corresponding features of cerebellar dysfunction including: 1. the vermis and anterior lobe with ataxic posture and gait, characterized by staggering, swaying and titubation, 2. the cerebellar hemispheres with ataxic kinetic limb movements, characterized by intention and action tremor, dysdiadochokinesis, dysmetria, dysarthria and dysrhythmia of speech, and 3. the vermis and flocculus with oculomotor dysfunction, including saccadic eye movements, disorders of smooth pursuit, fixation instability and ocular alignment disorders, see Table II.(19) In addition to the cerebellar role in coordinative motor function, the cerebellum also plays a role in cognitive and limbic functioning.(20) Through cerebro-cerebellar pathways, the cerebellum may affect language, working memory, visuo-spatial organization and procedural learning.(21–24) Current data indicate that the cognitive domains of the cerebellum are located in the hemispheric cortex of the posterior lobe, whereas the limbic domains are located in the posterior vermis.(25) Cerebellar tumor surgery of these cognitive and limbic domains can induce the cerebellar mutism syndrome, resulting in neuropsychiatric symptoms, mood disturbances and mutism.(20,26) The underlying pathogenesis is still unknown and there are no identified genetic associations.(20,26)

**2.2. Exclusion of Cerebellar Ataxia Mimics**

After recognition of ataxic features, the first step is to exclude cerebellar ataxia mimics, such as sensory ataxia. Damage to the peripheral nerves, spinal ganglia and dorsal columns can disturb the cerebellar input signals, causing sensory ataxia, whereas the cerebellum itself may still be intact. Analogous to cerebellar ataxia, sensory ataxia may cause a broad based gait and dysmetria. Moreover, cerebellar and sensory ataxia can even concur in the same patient (e.g. in patients with Friedreich’s ataxia or Ataxia with vitamin E deficiency (AVED)), which may complicate distinction. In such cases, one can recognize a strong sensory component when eye closure causes an instantaneous worsening of movement coordination or when deep tendon reflexes are reduced or absent.   
Other potential mimics of cerebellar ataxia are vestibular dysfunction (often associated with hearing impairment, vertigo and gaze-evoked nystagmus), developmental conditions (including physiological age-related movement disorder-like features, developmental coordination disorder (DCD), myopathies, connective tissue disorders and hypotonia with hypoactive muscle activation (HHM).(27–33) Finally, EOAc should be distinguished from action myoclonus and dystonic tremor, which may sometimes mimic the features of an ataxic intention tremor.

*2.2.1 Developmental Coordination Disorder (DCD)*

In children with Developmental Coordination Disorder (DCD), coordination impairment by clumsiness should be distinguished from the presence of an ataxic movement disorder. According to the DSM-V criteria, DCD is characterized as a developmental disorder, not attributable to physiologic immaturity, resulting in non-progressive motor incoordination, interfering with daily activities or academic achievements, after exclusion of neurological, visual and/or intellectual disorders.(34) Although children with DCD might also reveal mild, non-progressive ataxic features, careful longitudinal assessment of the above mentioned DCD criteria could help to differentiate between EOAc and DCD. Longitudinal assessment of DCD criteria should include a broad functional evaluation of the participation in daily activities, communication, cognitive and behavioral functioning. Furthermore, the presence of specific oculomotor symptoms and/or other, (non-)neurologic symptoms may help to distinguish EOAc from DCD patients (see Table II and III).

**2.3 Exclusion of acquired ataxia**

All acquired causes of ataxia (including intoxications, medication side effects, vascular, inflammatory, infectious and deficiencies) should be distinguished from genetic and/or metabolic causes underlying EOAc, see supplementary data I. This can be performed by a careful evaluation of the disease history ((sub-)acute presentation), MRI and laboratory investigations.

**3. Step 2: Evaluation of non-ataxic symptoms (INAS) and quantification of ataxia symptoms (SARA)**

**3.1 Inventory of comorbid non-ataxic signs**

The EOAc phenotype is often complex,(5,6) involving multiple neurologic and non-neurologic signs and symptoms. Comorbid non-ataxic signs can be systematically assessed by the Inventory of Non- Ataxic Signs (INAS), see Table III.(35,36)

**3.2 Quantification of the ataxia severity**

When the presence of EOAc is established, the severity of the ataxic features can be evaluated by clinical rating scales, including the International Cooperative Ataxia Rating Scale (ICARS),(37) the Scale for Assessment and Rating of Ataxia (SARA)(38) and the Brief Ataxia Rating Scale (BARS).(39) A brief description of pediatric ataxia rating scales is provided in supplementary data II. In children older than eight years of age, we have shown that these ataxia rating scales can be reliably assessed (Inter-observer reliability; Intraclass Correlation Coefficient (ICC) *0.91 – 0.99*).(40) Due to its brevity, high reliability and frequent application in adult patients, the SARA is often preferred.(41) The CACG-EPNS has recently validated the SARA for age, allowing an accurate longitudinal interpretation of scores against the physiologic age-related values in healthy young children.(29,41)For the assessment of pediatric EOAc disease progression, standardized SARA video-recordings are thus considered as useful. However, it is important to realize that eye movements should be additionally assessed, as oculomotor function is not included in the SARA, see figure 1 and Table II.(17)

**4. Step 3: Family history and distinct phenotypes**

A positive family history with an identified gene defect may prompt direct sequencing of the associated gene. Other information, such as ethnicity and region-specific morbidity may increase the statistical likelihood of a specific gene defect. Trinucleotide repeat expansions, either inherited or occurring *de novo*, are associated with dominantly inherited spinocerebellar ataxias in children (see also Table IV). Trinucleotide repeat expansions can reveal anticipation, implicating the occurrence of an earlier and more severe disease presentation in successive generations. The appearance of specific features such as downward gaze palsy, telangiectasia and xanthomas may prompt direct testing of the associated gene (see Table III).

*4.1 Friedreich’s ataxia*

Friedreich’s ataxia is one of the most commonest causes of EOAc, presenting with a distinct phenotype. Friedreich’s ataxia is an autosomal recessively inheritable disease caused by a bi-allelic pathogenic variant in *FXN* encoding the frataxin protein. Most patients are diagnosed with an abnormally expanded GAA tri-nucleotide repeat on both alleles, although compound heterozygous mutations involving a pathogenic GAA repeat expansion on one allele and an intragenic inactivating pathogenic variant on the other allele may also be present.(42–44) The clinical presentation is associated with ataxic cerebellar dysfunction, and additionally with loss of deep tendon reflexes, pyramidal tract signs, proprioception, vibration sense, sensory neuronopathy, hypertrophic cardiomyopathy, myopathy, scoliosis, optic neuropathy, diabetes mellitus and hearing disturbances.(42,43,45,46) Oculomotor testing may reveal fixation instability with square wave jerks (Table II), both during rest and smooth pursuit.(42) If the clinical phenotype resembles that of Friedreich’s Ataxia, one should directly test for it, as NGS techniques will not detect repeat disorders.

**5. Step 4: Brain MRI**

In absence of a positive clue, the next step is to perform a brain MRI.(47–50) The recommended MRI protocol comprises T1- andT2-weighted images, Fluid-Attenuated Inversion Recovery (FLAIR), Diffusion Weighted Images (DWI) and Susceptibility Weighted Images (SWI) (to exclude hemorrhage or traumatic brain injury), and consideration of subsequent gadolinium administration and reconstruction in multiple planes (coronal, sagittal and axial).(47–50) Gadolinium administration may be considered for the exclusion of acquired causes. When there is a congenital disease presentation, gadolinium administration should be restricted, as multiple dosages could lead to depositions in the globus pallidus, dentate nucleus, substantia nigra and red nucleus. (51) On midsagittal T1- and T2-weighted images, the sizes of the posterior fossa, vermis, fourth ventricle, supra-vermian cistern and brainstem volumes can be easily evaluated.(49,50) In the presence of cerebellar hypoplasia and cerebellar atrophy, secondary enlargement of the fourth ventricle and the supra-vermian cistern may evolve.(49,50) In coronal planes, volumes of cerebellar vermis and hemispheres can be compared.(50) The size, morphology and signal intensity of the cerebellar vermis, cortex, cerebellar white matter and dentate nucleus can be determined on axial T1- and T2-weighted images. Abnormalities of the cerebellar white matter and cortex can be assessed by T2-weighted images.(50)

Three relevant MRI patterns of hindbrain abnormalities are Joubert syndrome, Dandy Walker malformation and pontocerebellar hypoplasia.(52) In Joubert syndrome, the molar tooth sign is considered as pathognomonic. This sign is identifiable on axial planes, consisting of a deep inter-peduncular fossa and elongated, horizontally placed superior cerebellar peduncles (figure 2a).(52) In patients with a Dandy Walker malformation there is hypoplasia and anti-clockwise upward rotation of the cerebellar vermis with cystic dilatation of the fourth ventricle, upward displacement of the tentorium (figure 2b) and the presence of the “tail sign”, a linear hypointensity in T2-weighted images at the inferior portion of the vermis showing a radiological appearance of a ‘tail’. (52–54) Pontocerebellar hypoplasia is characterized by cerebellar hypoplasia (mainly of the cerebellar hemispheres with relative preservation of the vermis) and hypoplasia of pontine structures. In the coronal plane these features can be characterized by a “dragonfly sign” (figure 2c).(52) All three patterns of hindbrain malformations may vary in severity and may also include other infra- and supra-tentorial abnormalities.(52,53) If specific features corresponding with one of the three patterns of hindbrain malformations are present, it is advisory to perform direct genetic testing using a specific NGS hindbrain malformation subpanel, see supplementary Tables II – IV. It is indicated that medial T2-hypointense and lateral T2-hyperintense pontine stripes on MRI may provide a unique diagnostic biomarker for the Charlevoix-Saguenay (ARSACS) syndrome, prompting direct genetic testing for mutations in the *SACS* gene (figure 2d).(55–57) Another distinctly recognizable MRI pattern is rhombencephalosynapsis (figure 2e). Rhombencephalosynapsis is characterized by the absence of the vermis and fusion of the cerebellar hemispheres. This can be evaluated on T2-weighted coronal images in the most posterior section. Rhombencephalosynapsis is an important key feature of Gómez-López-Hernández syndrome (with other features such as acquired microcephaly, parietal alopecia, trigeminal anesthesia and craniofacial dysmorphic signs). Some patients with rhombencephalosynapsis may also reveal features of VACTERL association. Rhombencephalosynapsis is associated with congenital hydrocephalus due to hypoplasia or a stenosis of the aqueduct. For other recognizable and suggestive MRI patterns in cerebellar disease, see Doherty et al.(58)

In the absence of specific clues, determination of cerebellar hypoplasia or atrophy may help to differentiate between diagnostic groups. Atrophy can be diagnosed when the cerebellar volume decreases between two successive MRIs. The degree of atrophy depends on the disease stage. This implies that atrophy cannot be diagnosed on basis of a single MRI. However, due to “ceiling effects” at later stages, progression of volume loss may sometimes become hardly detectable during follow-up.(50) The differential diagnosis of cerebellar hypoplasia and atrophy is extensive, involving many genetic and metabolic diseases, see Table V and VI.(49,50) Beside the hypoplasia or atrophy, the radiological differential diagnosis depends on the comorbidity with other MRI abnormalities (such as hypomyelination, other white matter abnormalities, basal ganglia abnormalities etc.), see Table VI. The use of brain MRI is also crucial for the detection of other congenitally acquired cerebellar malformations, such as for instance malformations by cerebellar disruption or hemorrhage. Finally, when abnormalities are consistent with a leukodystrophy, one should consider a specific approach for the determination of “leukodystrophy MRI patterns” .(59)

**6. Step 5: Laboratory investigations**

Laboratory testing can both reveal some of the genetic and acquired ataxias. For laboratory testing of blood, urine and/or cerebrospinal fluid, see Table VII. Disorders that are associated with acquired ataxia are considered at the first step of the algorithm (see also supplementary data I).

*6.1 Genetic ataxias associated with biochemical alterations*

Ataxia with Vitamin E deficiency (AVED) concerns a rare, autosomal recessively inherited disorder caused by a mutation in the alpha-tocopherol transfer protein (*TTPA* gene), with a relatively high prevalence in Tunisia and other Mediterranean regions.(60–67) AVED patients may manifest with a heterogeneous phenotype and disease severity, even within families.(65) The pediatric disease onset may range from 4-18 years of age.(60,61,64,65) The clinical presentation of AVED may resemble the phenotype of Friedreich’s ataxia with progressive gait and limb ataxia, dysarthria, posterior column involvement, areflexia and extensor plantar responses.(60–67) However, in such cases, comorbid hypertrophic cardiomyopathy may be indicative of Friedreich’s ataxia,(64) and comorbid myoclonus, with low serum levels of vitamin E (in presence of normal cholesterol, triglycerides and beta-lipoproteins levels) of AVED.(60–67) Treatment consists of supplementary vitamin E in high doses, which can stabilize and/or ameliorate the neurological deficits. Early therapeutic intervention is associated with a better prognosis.(62–65)

Abetalipoproteinemia is a metabolic disorder caused by an autosomal recessively inherited mutation in the microsomal triglyceride transfer protein (*MTTP* gene).(68–70) Abetalipoproteinemia is characterized by severe lipid malabsorption from birth onwards. Diarrhea will develop after the first ingestion of milk.(68–70) Due to chronic fat malabsorption, the child fails to thrive and a deficiency of fat-soluble vitamins A, D, E and K occur. The neurological manifestations of abetalipoproteinemia resemble AVED, since both diseases share vitamin E deficiency as a pathogenic factor.(71) However, in contrast to AVED, abetalipoproteinemia is also associated with low serum levels of cholesterol, triglycerides, apo-B proteins, other fat-soluble vitamins (A, D and K) and acanthocytes in microscopic blood smears.(68,70) Abetalipoproteinemia is treated by a low fat diet and supplementation with fat-soluble vitamins.(68) Vitamin E supplementation may stabilize and/or even improve neurological symptoms.(62–65)

Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessively inherited metabolic disorder caused by a mutation in the *CYP27A1* gene.(72–76) CTX is characterized by multi-organ involvement with delayed symptom onset (mean age of presentation is 19 years).(74,76) In children, early disease manifestations may include cataract and intractable diarrhea, followed by tendon xanthomas, neurological symptoms and psychomotor retardation.(74) The neurological presentation of CTX can be subdivided into a classic phenotype with cerebellar signs, parkinsonism and epilepsy; and a spinal phenotype with a chronic myelopathy.(73–75) Other co-occurring neurological features are pyramidal tract signs, dystonia, palatal myoclonus, cognitive deficits and psychiatric symptoms.(73–75) Biochemically, CTX is characterized by a five- to tenfold increase in cholestanol, normal to low levels of cholesterol and increased urine excretion of urine bile acid alcohol.(77) Neuroimaging plays a significant role in the diagnosis of CTX, demonstrating cerebellar atrophy with white matter changes and increased signal of the dentate nuclei on T2-weighted images.(78,79) CTX is treated by the administration of chenodeoxycholic acid which can improve the neurologic symptoms and prognosis.(80,81)

Ataxia with oculomotor apraxia type 1 (AOA1) is an autosomal recessive disorder caused by a mutation in the *APTX* gene, encoding the aprataxin protein. Mean age of disease onset is around 4 years.(82,83) The presenting sign is a slowly progressive ataxic gait. Patients frequently show deficits in initiating horizontal saccades, which defines “oculomotor apraxia”, sometimes compensated by ipsilateral head turning to facilitate saccade initiation. The oculomotor apraxia is present in about 85% of patients with AOA1. AOA1 clinically resembles Friedreich’s ataxia, but AOA1 does not include a cardiomyopathy. Additional movement disorders such as dystonia, chorea and myoclonus are much more frequent in AOA1 than in Friedreich’s ataxia.(82,83) Moreover, cerebellar atrophy on MRI is more frequently present in AOA1, whereas it is mostly absent in early to mid-stages of Friedreich’s ataxia. Supporting biochemical changes include low albumin, and increased blood cholesterol levels. There is no curative treatment for AOA1.(83)

Ataxia with oculomotor apraxia type 2 (AOA2) is caused by bi-allelic mutations in the gene *SETX* encoding senataxin, the second most common recessively inherited ataxic disorder in young adults.(83,84) The AOA2 phenotype resembles AOA1, with respect to a progressive cerebellar ataxia and the co-occurrence of dystonia.(83–87) However in AOA2, the disease onset occurs later (between 11 and 20 years), the neuropathy seems less severe, and oculomotor apraxia is less frequently present (50%) compared to AOA1.(83) Biochemically, AOA2 shows increased alpha-fetoprotein (AFP), but to a lesser extent than in Ataxia Telangiectasia (AT).(82–87) There is no curative treatment for AOA2.

Ataxia telangiectasia (AT) is a rare, recessive, neurodegenerative, DNA repair disorder caused by bi-allelic mutations in the *ATM* gene.(88) Clinically, classic AT is characterized by a cerebellar gait disorder in toddlers, with slow progression over years. Around the age of 5-8 years, oculo-cutaneous telangiectasia may develop.(88) Associated neurological features include both hypokinetic and hyperkinetic (chorea and dystonia) movement disorders, which may prevail over the ataxia.(89) Peripheral neuropathy commonly develops later in the disease course.(90) Non-neurological signs of AT include immune deficiencies (causing frequent infections) and malignancies (especially lymphoid).(88) Biochemically, AT is characterized by elevated AFP in serum (in 95% of the patients), which increases during their lifetime, providing a reliable biomarker.(91) Treatment of the neurological signs is symptomatic. However, the systemic manifestations (such as immune deficiency) can be treated with immune-globulins. In AT patients, X-ray examinations should be avoided, due to the propensity of severe radiation induced tissue damage.(88)

**7. Step 6: Array investigation**

In patients with combined features, cognitive impairment, dysmorphism and/or other congenital abnormalities, array CGH (Comparative Genomic Hybridization) may reveal Copy Number Variants (CNV). For chromosomal and/or syndromic diseases presenting with ataxia and/or radiological characteristics of cerebellar hypoplasia/atrophy, see Table V and VI.(49,50)

**8. Step 7: Next Generation Sequencing (NGS)**

Next-generation sequencing (NGS) is the catch-all term for modern sequencing technologies. These include testing of specific gene panels (Targeted Resequencing Panels (TRS)), of coding regions (Whole Exome Sequencing (WES)) with or without a filter for specific genes and of the entire genome (Whole Genome Sequencing (WGS)).(9,10) In recent years, many laboratories apply WES as a diagnostic NGS strategy for the majority of diagnostic applications. It is important to realize that there are some limitations to these novel techniques. First, one should consider the targeted genes of the panel or filter. Secondly, at this moment NGS does not detect repeat expansion disorders and large rearrangements (deletions and duplications).(9,92) Mutations in noncoding parts of the genome (such as deep intronic regions or promotor regions) can only be detected with WGS. Thirdly, EOAc patients may often present with a mixed phenotype, complicating the selection of the gene panel. Finally, mutations in mitochondrial DNA (mtDNA) might be missed by NGS techniques, requiring separate mtDNA analysis. However, in case of suspicion of a mitochondrial DNA disorder, recent studies advise to start with performing WES analysis first, since this approach has a higher diagnostic yield than with targeted mtDNA analysis (30% of genetic defects were missed with MitoCarta only).(93) For an overview of mitochondrial disorders that are associated with cerebellar ataxia, see supplementary Table V.(94)

These NGS techniques, including EOA gene panels (see supplementary Table I) provide an important step in the algorithm. Firstly, one may perform a WES with a specific EOA gene panel, or another gene panel targeted at co-morbid features. When negative, the WES could be analyzed in total to detect *de novo* mutations as well as presentations of a known Mendelian disease, which has not frequently been associated with EOA.(95) For correct interpretation of the genomic results (including a variant of unknown significance (VUS)), adequate phenotypic assessment and trio analysis of the index patient with both parents is advisory. In absence of abnormalities, tri-nucleotide repeat expansion disorders and small deep intronic point mutations should be considered. These abnormalities are not detected by current targeted WES NGS techniques. Finally, it is important to realize that the provided gene-list (see supplementary Table I), should be continuously up-dated in the future, as newly discovered genes should be added to it, as well.

**9. EOA database inclusion**

As implicated by the enormous variety in underlying genetic and/or metabolic disorders, the EOAc disease spectrum is large. Although application of NGS techniques may result in a higher diagnostic yield, it has been indicated that about 60-70% of EOAc patients may still remain undiagnosed.(96) This is attributable to the potential presence of unrecognized monogenic disorders, complex genetic disorders and disorders caused by epigenetic factors. In this perspective, the CACG-EPNS has collaborated with the adult Ataxia Study Group (ASG) to assemble all EOAc patients in one collaborative international database (http://arca-registry.org/) from childhood to adulthood (presently including more than 500 patients, from more than 25 centers worldwide). We hope that a uniform diagnostic algorithm will contribute to 1. novel insights into the longitudinal disease course of underlying disorders; 2. identification of new genes, unraveling complex genetic disorders and the identification of possible epigenetic factors; 3. development of new treatment strategies in larger homogeneous patient groups; and 4. characterization of transparent markers for monitoring.(6)

**10. Conclusion**

Early Onset Cerebellar Ataxia (EOAc) comprises a large group of rare disorders, with heterogeneous genotypes and phenotypes. In children with early onset cerebellar ataxia, this algorithm may hopefully contribute to the diagnostic process, support the recognition of the underlying diagnoses and provide conditions for optimal usage and interpretation of innovative NGS techniques in EOAc patients.

**Acknowledgements**

This algorithm has been written by the members of Childhood Ataxia and Cerebellar Group of the European Pediatric Neurology Society (CACG-EPNS). The EPNS is greatly acknowledged for their support in the organisation of the expert meetings.

**Funding**

M.S. was supported by a grant of the Else Kröner-Fresenius-Stiftung;

E.B. and G.V. were supported by a grant from the Italian Ministry of Health Ricerca Finalizzata NET-2013-02356160.

A.M. was supported by grant PI15/01791from Instituto Carlos III, Spain

I.C. was supported by grant N-2018-L from Stichting NeMO

Captions

**Figure 1: Clinical diagnostic algorithm in Early Onset Ataxia (EOA)**

This figure displays the diagnostic algorithm for the diagnostic process of Early Onset Ataxia. The consecutive steps of the algorithm will lead the clinician through the diagnostic process. #See Table II for oculomotor features in EOAc and table III for the Inventory of non-ataxic signs (INAS); ^See Table I and IV for paroxysmal ataxic disorders and (tri)nucleotide repeat disorders, respectively. The box “other abnormalities” of the MRI also includes cerebellar hypoplasia and cerebellar atrophy (for genetic differential diagnosis, see Table VI). +See Table V and VI for the differential diagnosis on cerebellar hypoplasia and cerebellar atrophy on MRI, respectively. $See Table VII for additional laboratory investigations; \*See supplementary Table II – IV for hindbrain malformation panels; @ For NGS we advise to perform Whole Exome Sequencing (WES) first with a specific gene panel (see supplementary Table I for the whole EOA NGS gene filter), in case this is negative the WES can be opened to review all genes. %In case of specific clues pointing to a mitochondrial disorder consider mitochondrial DNA analysis. &In case of no diagnosis consider re-evaluation after >1 year. INAS = Inventory of Non-Ataxic signs; MRI = Magnetic Resonance Imaging; NGS = Next Generation Sequencing; EOAc = Early Onset Cerebellar Ataxia.

**Figure 2: Examples of specific hindbrain malformations on MRI**

a) T2 weighted axial planeshowing the typical "Molar tooth sign" of a patient with Joubert syndrome. The figure illustrates the deep inter-peduncular fossa of the mesencephalon. Together with the elongated and horizontally placed superior cerebellar peduncles gives the appearance of a "molar tooth".

b) T2 midsagittal plane of a patient with Dandy Walker Malformation, showing enlargement of the posterior fossa with an upward displacement of a hypoplastic cerebellar vermis. There is also a cystic dilatation of the fourth ventricle with upward displacement of the tentorium cerebelli.

c) T2 coronal plane showing distinct hypoplasia of both cerebellar hemispheres (as indicated by the arrows) with relative preservation of the cerebellar vermis, often referred to as a "dragonfly" appearance in patients with pontocerebellar hypoplasia, as seen in this patient with PCH type 2. Hypoplasia of the pontine structures can be evaluated on a midsagittal T2-weighted image (not shown).

d) T2 axial plane of the pons in a patient with ARSACS (*SACS* gene) showing distinct medial *hypo*intense pontine stripes. Laterally there is a *hyper*intense signal of the pons, as indicated by both arrows.

e) T2 coronal plane of the posterior part of the cerebellum. There is a clear fusion of both cerebellar hemispheres with the absence of the vermis, indicative of a rhombencephalosynapsis.

**Table I: Genes causing paroxysmal ataxic disorders in children**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Gene (OMIM)*** | ***Disease name*** | ***Inheritance*** | ***Additional features*** |
| *KCNA1* (176260) | Episodic Ataxia type 1; (EA1) | AD | Between attacks myokymia and epilepsy |
| *CACNA1A (*601011) | Episodic Ataxia type 2; (EA2) | AD | Between attacks nystagmus and gait ataxia |
| *1q42* (606554) | Episodic Ataxia type 3; (EA3) | AD | # |
| *CACNB4* (601949) | Episodic Ataxia type 5; (EA5) | AD | Between attacks down beat and gaze-evoked nystagmus |
| *SLC1A3* (600111) | Episodic Ataxia type 6; (EA6) | AD | Between attacks horizontal gaze-evoked nystagmus |
| *PRRT2* (614386) | Paroxysmal Kinesogenic Dyskinesia (PKD) | AD | Dystonia and/or chorea during an attack |
| *SLC2A1* (138140) | | Glucose Transporter deficiency  (GLUT-1) | AD | In children associated with epilepsy and/or epileptic encephalopathy |
| *ATP1A3* (182350) | | CAPOS (Cerebellar ataxia, Areflexia, Pes Cavus, Optic atropy and Sensineuronal deafness) | AD | Areflexia, pes cavus, optic atrophy and sensineuronal deafness. Can start as episodic ataxia, provoked by fever. The disease course is mostly progressive |

**Legend**: OMIM = Online Mendelian Inheritance in Man; AD= Autosomal dominant; AR = Autosomal recessive. # episodic ataxia type 3 is not associated with a specific gene mutation, but with a known locus on chromosome 1q42.

**Table II: Cerebellar oculomotor features**

|  |  |  |
| --- | --- | --- |
| **Cerebellar oculomotor features** | **Description of the oculomotor feature** | **Diseases in which these features could be present** |
| ***Saccadic eye movements*** |  |  |
| Saccadic dysmetria | Either hypometria or hypermetria | AT; FRDA; AOA1; AOA2; Tay Sachs; EA2; SCA1; SCA2; SCA3; SCA17; SCA28 |
| Saccade initiation delay (ocular motor apraxia) | Delayed initiation of saccades. Patients use their head (or they blink) to rapidly shift their direction of gaze | AOA1; AOA2; AT; Joubert syndrome |
| ***Smooth pursuit of eye movements*** |  |  |
| Slow smooth ocular pursuit | Jerky tracking of a visual target  (visual as saccades) | FRDA; SCA1; SCA2 |
| ***Signs of fixation instability*** |  |  |
| Gaze-evoked nystagmus | Ocular oscillations observed while the eyes are off center. Gaze-evoked nystagmus can either be horizontal or vertical. The fast phase is in the direction of the gaze. | FRDA; AOA1; AOA2; AT; EA2; SCA1; SCA2; SCA3; SCA5; SCA6; SCA17 |
| Rebound nystagmus | Transient nystagmus observed when the eyes are midcenter. The fast phase beats to the opposite side of the initial direction of gaze | FRDA; SCA1; SCA3; SCA6 |
| Downbeat nystagmus | During midposition, nystagmus occurs with the fast phase downwards. The nystagmus is exacerbated during downgaze and lateral gaze. | AT; EA2; SCA6; SCA5; SCA17 |
| Upbeat nystagmus | During midposition, nystagmus occurs with the fast phase upwards. The nystagmus is exacerbated during upgaze. |  |
| Periodic alternating nystagmus | Horizontal nystagmus when the eyes are in midposition. The fast phase changes direction gradually after a silent period | FRDA; AT; SCA6 |
| Ocular flutter | Involuntary conjugate, unpredictable horizontal back-to-back saccades during attempted fixation | FRDA |
| Opsoclonus | Involuntary conjugated multi-directional back-to-back saccades observed when the patient tries to fixate | OMA syndrome |
| Square wave jerks/ microsaccadic oscillations | Intrusive, unwanted involuntary and conjugated saccades which takes the eyes off fixation | Healthy children\*; FRDA; AOA1; AOA2; AT; EA2; SCA1; SCA2; SCA3; SCA6 |
| Ocular bobbing | Fast downward movement followed by a slow backward movement to the primary position |  |
| ***Ophthalmoparesis*** |  |  |
| Ophthalmoparesis | Variant degree of paresis of oculomotor muscles | Mitochondrial disorders |

**Legend:** Oculomotor features observed in cerebellar diseases, subdivided according to four subcategories. All features are described and diseases in which these features could be present are given in this table. AT = Ataxia Telangiectasia; FRDA = Friedreich’s ataxia; AOA = Ataxia with Oculomotor Apraxia; EA = Episodic ataxia; SCA: Spinocerebellar Ataxia; OMA = Opsoclonus-Myoclonus-Ataxia syndrome.\*Square wave jerks are also physiologically present in up to 90% of children (until 19 years of age)(19,97)

**Table III: Inventory of non-ataxia signs (INAS)**

|  |  |  |
| --- | --- | --- |
| **Non-ataxia signs** | **Diseases in which this symptom is present** | |
| Hyperreflexia | | SCA and SCAR |
| Areflexia | | FRDA; AVED; AT; Abetalipoproteinemia; AOA 1-4; CAPOS |
| Extensor plantar response | | FRDA; AVED; Abetalipoproteinemia; AOA type 1-4 |
| Spasticity | | SCA and SCAR |
| Paresis | | FRDA, *SYNE1*, Marinesco-Sjögren syndrome |
| Muscle atrophy | | Marinesco-Sjögren syndrome, AOA1, *SYNE1*, *ARSACS* |
| Fasciculations | | SCAR type 8 |
| Myoclonus | | SCA type 13 and 14  AOA type 1 and 2, POLG, other mitochondrial diseases, OMA |
| Rigidity | | Different types of NBIA; Wilson disease; SCA type 2 |
| Chorea/Dyskinesia | | Different types of NBIA; Wilson disease; AT; SCA type 17, POLG, AOA2, |
| Dystonia | | Different types of NBIA; Wilson disease; AOA type 1 and 2; AT; SCA type 2; *SYNE1* |
| Resting tremor | | AT; NBIA; Wilson disease |
| Sensory symptoms | | Several ataxic disorders are associated with a (poly)neuropathy |
| Downward gaze palsy# | | Niemann Pick type C |
| Oculomotor apraxia# | | AOA type 1-4; AT; Joubert syndrome |
| Xanthomas# | | CTX |
| Cataract#  Optic atrophy# | | CTX; mitochondrial diseases; Marinesco-Sjögren syndrome  FRDA; CAPOS; *KIF1A* |
| Myokymia# | | EA1 |
| Telangiectasias# | | AT |
| Deafness# | | Peroxisomal disorders; mitochondrial diseases; CAPOS; FRDA |
| Bilateral alopecia# | | Gomez-Lopez-Hernandez syndrome |

**Legends**: Summary of non-ataxic comorbidity; Table adapted from the Inventory of non-ataxia signs for pediatric EOA,(35,36) which clinicians should look for during neurological examination.

# These items are not involved in the INAS, but may provide important clues. ARSACS = Autosomal recessive spastic ataxia of Charlevoix-Saguenay; AVED = Ataxia with Vitamin E Deficiency; AOA = Ataxia with Oculomotor Apraxia; CAPOS = Cerebellar ataxia, Areflexia, Pes Cavus, Optic atropy and Sensineuronal deafness; GOSR2 = North Sea Progressive Myoclonus Epilepsy syndrome; FRDA= Friedreich’s ataxia; *KIF1A* = Spastic paraplegia type 30; EA1 = Episodic ataxia type 1; SCAR = Spinocerebellar Ataxia Autosomal Recessive; SCA = Spinocerebellar Ataxia; *SYNE*= Spinocerebellar ataxia autosomal recessive type 8; OMA; Opsoclonus-myoclonus-ataxia syndrome; NBIA = Neurodegeneration with Brain Iron Accumulation; AT = Ataxia Telangiectasia; CTX = Cerebrotendinous xanthomatosis

**Table IV: Genetic ataxias caused by a (tri)nucleotide repeat disorder.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ***Gene (OMIM)*** | ***Repeat*** | ***Disease name*** | ***Inheritance*** | ***Additional features*** |
| *FXN* ( 606829) | GAA | Friedreich’s ataxia | AR | Peripheral neuro(no)pathy, cardiomyopathy, scoliosis, pes cavus |
| *ATXN2* (601517) | CAG | Spinocerebellar ataxia type 2 | AD | Parkinsonism, myoclonus |
| *CACNA1A* (601011) | CAG | Spinocerebellar ataxia type 6 | AD |  |
| *ATXN7* (607640) | CAG | Spinocerebellar ataxia type 7 | AD | Retinal changes |
| *ATXN8* (613289) | CTG | Spinocerebellar ataxia type 8 | AD | Pyramidal signs |
| *ATXN10* (611150) | ATTCT | Spinocerebellar ataxia type 10 | AD | Epilepsy, pyramidal signs and cognitive problems |
| *PPP2R2B* (604325) | CAG | Spinocerebellar ataxia type 12 | AD | Epilepsy, dementia and parkinsonism |
| *TBP* (600075) | CAG/CAA | Spinocerebellar ataxia type 17 | AD | Psychiatric features and chorea (Huntington like) |
| *HTT* (613004) | CAG | Huntington | AD | Psychiatric features, chorea and parkinsonism |

**Legend:** Trinucleotide repeat disorders and corresponding genes. Inheritance and additional features are given in this table. OMIM = Online Mendelian Inheritance in Man; AR = Autosomal recessive; AD = Autosomal dominant.

**Table V: Differential diagnosis of cerebellar hypoplasia on MRI**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Neuroimaging pattern*** | | ***Disease group*** | ***Disease/anomalies*** |
| Unilateral cerebellar hypoplasia | | Acquired | Second and/or third trimester hemorrhage |
|  | | Genetic | PHACE(S) syndrome; Familial porencephaly (*COL4A1*-mutation) |
| Cerebellar hypoplasia with mainly vermis involvement | | Posterior fossa malformations | Dandy Walker malformation; Joubert syndrome; Rhombencephalosynapsis |
|  | |  | Congenital ocular apraxia type Cogan |
|  | | Genetic syndromes | Acrocallosal syndrome; Gillespie syndrome; Beckwith-Wiedemann syndrome; autism associated chromosome 22q13 terminal deletion. |
| Global cerebellar hypoplasia | | Prenatal infections | Congenital CMV infection |
|  | | Prenatal teratogens | Antiepileptic drugs (valproate; phenytoin); retinoic acid; alcohol; cocaine |
|  | | Chromosomal abnormalities | Trisomy (13, 18 and 21); partial trisomy 12q; monosomy 21q; trisomy 15 mosaicism; monosomy 1p36; ring chromosome 6; de novo X;8 translocation; 13q12.3-q14.11 deletion |
|  | | Metabolic disorders | Adenylosuccinase deficiency; Smith-Lemli-Opitz |
|  |
|  |  |  | syndrome; Molybdenum cofactor deficiency and isolated sulfite oxidase deficiency; copper metabolism disease (*SLC33A1*-mutation); Zellweger syndrome; nonketotic hyperglycinemia; mitochondrial disorders (Leigh disease, pyruvate dehydrogenase deficiency; Mucopolysaccharidoses (type I and II); |
|  | | Genetic syndromes | Ritscher-Schinzel (3C) syndrome; Hoyeraal-Hreidarsson syndrome; CHARGE syndrome; Endosteal sclerosis; oculocerebrocutaneous (Delleman) syndrome; *IER3IP1*-mutation; |
|  | |  | neurofibromatosis type 1; pseudo-TORCH syndrome; velocardiofacial syndrome; oculodentodigital syndrome; Cohen syndrome; Cri du Chat syndrome; Pallister-Killian syndrome; Galloway-Mowat syndrome; Sengers syndrome; *OPHN1*-related X-linked intellectual disability |
|  | | Non-progressive cerebellar ataxias | *CA8; WDR81; ATP8A2; CWF19L1; ITPR1 (SCA15); PMPCA; ATP2B3 (X-linked) and CACNA1A* |
| Pontocerebellar hypoplasia | | Pontocerebellar hypoplasia as defined by Barth | PCH type 1-11 |
|  | | Cortical malformations | Lissencephaly (*RELN, VLDRL*, tubulin gens >> *LIS1, DCX, ARX*); polymicrogyria (tubulin genes, *GPR56*); periventricular nodular heterotopia (*FLNA*); primary microcephaly |
|  | | Metabolic diseases | Congenital disorders of glycosylation (mostly type 1a but also type 1q) |
|  | | Genetic disorders | CASK mutation; Cerebellar agenesis (*PTF1A*) |
|  | | Α-dystroglycanopathies | Walker-Warburg syndrome; muscle-eye-brain disease; Fukuyama disease |
|  | | Posterior fossa malformations | Pontine tegmental cap dysplasia |
|  | | Disruptive lesions | Cerebellar agenesis; cerebellar injury secondary to prematurity |

**Legend:** Differential diagnosis based on neuroimaging patterns of cerebellar hypoplasia seen on MRI. Copied and adapted with permission of Whiley and Sons publisher. (49)

**Table VI: Differential diagnosis of cerebellar atrophy on MRI**

|  |  |  |
| --- | --- | --- |
| ***Neuroimaging pattern*** |  | ***Diseases*** |
| Pure cerebellar atrophy |  | Ataxia telangiectasia; Ataxia Telangiectasia like disorder; Late-onset GM2 gangliosidosis; Ataxia with oculomotor apraxia type 1-4; PEHO syndrome; *CACNA1A*-mutation (episodic ataxia type 2; SCA6; familial hemiplegic migraine type 1); mevalonate kinase deficiency; SCAR7 (*TPP1* gene); SCAR10 (*ANO10* gene); SCAR13 (*GRM1* gene); SCAR14 (*SPTBN2* gene); SCA29 (point mutations in the *ITPR1* gene); predominant dystonia with cerebellar atrophy; *GRID2* mutation; Coenzyme Q10 deficiency; 4H (*POLR3B >POLR3A* mutations); *CTBP1* mutation; mitochondrial disorders |
| Cerebellar atrophy and hypomyelination |  | Pelizaeus-Merzbacher disease; Pelizaeus-Merzbacher like disease; Salla disease; 4H; H-ABC; galactosemia; trichothiodystrophy |
| Cerebellar atrophy and progressive white matter abnormalities | Frontal predominance | Infantile neuroaxonal dystrophy (*PLA2G6* mutation) |
|  | Periventricular predominance | Neuronal ceroid lipofuscinoses (particularly late-infantile type); Niemann-Pick type C; Adenylosuccinase deficiency |
|  | Occipital predominance | Early-onset peroxisomal disorders |
|  | Subcortical | L-2-hydroxyglutaric aciduria; Kearns-Sayre syndrome |
|  | Diffuse cerebral | Vanishing white matter disease; mitochondrial disorders |
|  | Cerebellar | Peroxisomal disorders; Cerebrotendinous xanthomatosis (CTX) |
|  | Brainstem | Wilson disease; Peroxisomal disorders; Leigh syndrome; dentate-rubral-pallido-luysian atrophy |
|  | Multifocal | Mitochondrial disorders; Galactosemia; Infantile neuroaxonal dystrophy; L-2-hydroxyglutaric aciduria. |
| Cerebellar atrophy and signal change of the dentate nucleus |  | L-2-hydroxyglutaric aciduria; CTX; Wilson disease; Succinic semialdehyde dehydrogenase deficiency |
| Cerebellar atrophy and cerebellar cortex T2-hyperintensity |  | Infantile neuroaxonal dystrophy; Marinesco-Sjörgen syndrome; congenital disorders of glycosylation 1a; Christianson syndrome; coenzyme Q10 deficiency; late infantile neuronal ceroid lipofuscinosis; pontocerebellar |
|  |  | hypoplasia type 7; some forms of non-progressive cerebellar ataxia; some mitochondrial disorders |
| Cerebellar atrophy and basal ganglia involvement | Calcifications | Kearns-Sayre syndrome; mitochondrial disorders; Cockayne syndrome; Aicardi-Goutières syndrome; MELAS |
|  | Atrophy | H-ABC; Wilson diseases (late); Huntington chorea (inconsistent) |
|  | Signal changes | Mitochondrial disorders; Wilson disease; 3-methylgutaconic aciduria |

**Legend:** Differential diagnosis of neuroimaging patterns with cerebellar atrophy. “Atrophy” can only be established after evaluating two successive MRI scans. The Table is subdivided according to MRI findings. Copied and adapted with permission of Whiley & Sons publisher. (50)

**Table VII: Additional laboratory investigations**

|  |  |
| --- | --- |
| ***Blood investigations*** | ***Disease groups and specific diseases*** |
| Leukocytes, thrombocytes, haemoglobin, ammonia, urea, creatine, liver transaminases, blood smear for acanthocytes, biotinidase, thyroid function (TSH, FT4), transferrin electrophoresis, acylcarnitines, lactate, CK, | Metabolic diseases including POLG1 |
| Vitamin B1, B12\* and E | AVED, abetalipoproteinemia (Wernicke encephalopathy) |
| Copper and ceruloplasmin | Wilson disease |
| Very long chain fatty acids, phytanic and pipecolic acid, bile acids | Peroxisomal diseases |
| Lysosomal enzymes\* (ASA, βgal, Hex A and B) | Lysosomal storage diseases |
| Anti NMDA\* | Auto-immune/paraneoplastic |
| Albumin  Cholestanol | AOA1 and AOA4, CTX |
| Cholesterol, triglycerides | Abetalipoproteinemia, AOA1 |
| Alpha-fetoprotein | AT, AOA2, AOA4 and POLG1 |
| ***Urine investigations*** | ***Disease group and specific diseases*** |
| Amino acids and organic acids  Bile acid alcohol  Urine Homovanillic acid (HVA) and Vanillylmandelic acid (VMA) | IEM  CTX  OMA (neuroblastoma) |
| ***Cerebrospinal fluid investigations*** | ***Disease group and specific diseases*** |
| Glucose\*, cell count\*, amino acids, lactate/pyruvate | IEM, GLUT1 and POLG1 |
| Anti-NMDA antibodies\* | Auto-inflammatory/Paraneoplastic |

**Legend:** Laboratory investigations to perform in EOAc. Abbreviations: TSH = Thyroid stimulating hormone; FT4 = Thyroxine; CK = Creatine kinase; ASA = Arylsulfatase A; βgal = Beta-galactosidase; HEX-A = Hexosaminidase A; HEX-B = Hexosaminidase B; NMDA = N=Methyl-D-Aspartate; GAD = Glutamic Acid Decarboxylase; POLG1 = Polymerase gamma 1 gene mutation; AVED = Ataxia with Vitamin E deficiency; CTX = Cerebrotendinous xanthomatosis; AOA1 = Ataxia with oculomotor apraxia type 1; AT = Ataxia telangiectasia; AOA2 = Ataxia with oculomotor apraxia type 2; AOA4 = Ataxia with oculomotor apraxia type 4; IEM =Inborn Errors of Metabolism; OMA = opsoclonus-myoclonus-ataxia syndrome; GLUT1 = Glucose transporter 1 deficiency.

\* These investigations indicate acquired ataxia and should thus be normal for inclusion in de European Early Onset Ataxia Database.

**References**

1. Singer HS, Mink JW, Gilbert DL, Jankovic J. Ataxia. In: Movement Disorders in Childhood. 2dth ed. Saunder Elsevier; 2010. p. 139–54.

2. Chio A, Orsi L, Mortara P, Schiffer D. Early onset cerebellar ataxia with retained tendon reflexes: prevalence and gene frequency in an Italian population. Clin Genet. 1993 Apr;43(4):207–11.

3. Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain. 2009 Jun;132(Pt 6):1577–88.

4. Musselman KE, Stoyanov CT, Marasigan R, Jenkins ME, Konczak J, Morton SM, et al. Prevalence of ataxia in children: a systematic review. Neurology. 2014 Jan;82(1):80–9.

5. Delgado MR, Albright AL. Movement disorders in children: definitions, classifications, and grading systems. J Child Neurol. 2003 Sep;18 Suppl 1:1.

6. Lawerman TF, Brandsma R, van Geffen JT, Lunsing RJ, Burger H, Tijssen MA, et al. Reliability of phenotypic early-onset ataxia assessment: a pilot study. Dev Med Child Neurol. 2016 Jan;58(1):70–6.

7. van Egmond ME, Verschuuren-Bemelmans CC, Nibbeling EA, Elting JW, Sival DA, Brouwer OF, et al. Ramsay Hunt syndrome: clinical characterization of progressive myoclonus ataxia caused by GOSR2 mutation. Mov Disord. 2014 Jan;29(1):139–43.

8. McCormick EM, Muraresku CC, Falk MJ. Mitochondrial Genomics: A Complex Field Now Coming of Age. Curr Genet Med Rep [Internet]. 2018 Jun 2;6(2):52–61. Available from: http://link.springer.com/10.1007/s40142-018-0137-x

9. Keogh MJ, Daud D, Chinnery PF. Exome sequencing: how to understand it. Pract Neurol. 2013 Dec;13(6):399–407.

10. Lemke JR, Riesch E, Scheurenbrand T, Schubach M, Wilhelm C, Steiner I, et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia. 2012 Aug;53(8):1387–98.

11. Dan B, Baxter P. Paediatric neurology: A year of DNA technology. Vol. 13, The Lancet Neurology. 2014. p. 16–8.

12. van Egmond ME, Lugtenberg CHA, Brouwer OF, Contarino MF, Fung VSC, Heiner-Fokkema MR, et al. A post hoc study on gene panel analysis for the diagnosis of dystonia. Mov Disord. 2017 Apr;32(4):569–75.

13. Renaud M, Tranchant C, Martin JVT, Mochel F, Synofzik M, van de Warrenburg B, et al. A recessive ataxia diagnosis algorithm for the next generation sequencing era. Ann Neurol. 2017 Dec;82(6):892–9.

14. Ghez C, Thach WT. Chapter 42: Cerebellum. In: Kandel E, Schwartz J, Jessel T, editors. Principles of neural sciences. 4th ed. New York: Mc Graw Hill; 2000. p. 823–50.

15. Steinlin M, Zangger B, Boltshauser E. Non-progressive congenital ataxia with or without cerebellar hypoplasia: a review of 34 subjects. Dev Med Child Neurol. 1998 Mar;40(3):148–54.

16. van Dijk T, Baas F, Barth PG, Poll-The BT. What’s new in pontocerebellar hypoplasia? An update on genes and subtypes. Orphanet J Rare Dis. 2018 Dec 15;13(1):92.

17. Vinet L, Zhedanov A. A “missing” family of classical orthogonal polynomials. Acta Neurochir (Wien). 1st ed. 2010 Nov 7;148(9):1017–1017.

18. Sival DA. Application of pediatric balance scales in children with cerebral palsy. Neuropediatrics. 2012 Dec;43(6):305–6.

19. Tarnutzer A, Straumann D, Salman M. Chapter 19: Neuro-opthalmologic assessment and investigations in children and adults with cerebellar diseases. In: Manto M, Huisman TA, editors. Handbook of Clinical Neurology. third edit. Elsevier; 2018. p. 305–27.

20. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain. 1998 Apr;121 ( Pt 4(4):561–79.

21. Ramnani N. Frontal Lobe and Posterior Parietal Contributions to the Cortico-cerebellar System. The Cerebellum. 2012 Jun;11(2):366–83.

22. Koziol L, Budding D, Andreasen N, D’Arrigo S, Bulgheroni S, Imamizu H, et al. Consensus Paper: The Cerebellum’s Role in Movement and Cognition. The Cerebellum. 2014 Feb;13(1):151–77.

23. Leggio MG, Chiricozzi FR, Clausi S, Tedesco AM, Molinari M. The neuropsychological profile of cerebellar damage: The sequencing hypothesis. Cortex. 2011;47(1):137–44.

24. Tedesco AM, Chiricozzi FR, Clausi S, Lupo M, Molinari M, Leggio MG. The cerebellar cognitive profile. Brain. 2011 Dec;134(12):3669–83.

25. Stoodley CJ, Valera EM, Schmahmann JD. Functional topography of the cerebellum for motor and cognitive tasks: An fMRI study. Neuroimage. 2012 Jan;59(2):1560–70.

26. Catsman-Berrevoets C, Patay Z. Cerebellar mutism syndrome. In: Handbook of Clinical Neurology. 2018. p. 273–88.

27. Kuiper MJ, Brandsma R, Vrijenhoek L, Tijssen MAJ, Burger H, Dan B, et al. Physiological movement disorder-like features during typical motor development. Eur J Paediatr Neurol. 2018 Jul;22(4):595–601.

28. Purves D, Lichtman J. chapter 12: Rearrangement of developing neuronal connections. In: Principles of Neural Development. first. Sinauer Associates; 1985. p. 271–300.

29. Lawerman TF, Brandsma R, Burger H, Burgerhof JGM, Sival DA. Age-related reference values for the pediatric Scale for Assessment and Rating of Ataxia: a multicentre study. Dev Med Child Neurol. 2017 Oct;59(10):1077–82.

30. Sival DA, Brunt ER. The International Cooperative Ataxia Rating Scale shows strong age-dependency in children. Dev Med Child Neurol. 2009 Jul;51(7):571–2.

31. Brandsma R, Spits AH, Kuiper MJ, Lunsing RJ, Burger H, Kremer HP, et al. Ataxia rating scales are age-dependent in healthy children. Dev Med Child Neurol. 2014 Jun;56(6):556–63.

32. Largo RH, Fischer JE, Rousson V. Neuromotor development from kindergarten age to adolescence: developmental course and variability. Swiss Med Wkly. 2003 Apr;133(13–14):193–9.

33. Sanger TD, Chen D, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Definition and Classification of Negative Motor Signs in Childhood. Pediatrics. 2006;

34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. In: American Psychiatric Association, editor. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. American Psychiatric Publishing, Inc; 2013.

35. Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology. 2011 Sep;77(11):1035–41.

36. Jacobi H, Rakowicz M, Rola R, Fancellu R, Mariotti C, Charles P, et al. Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument. Cerebellum. 2013 Jun;12(3):418–28.

37. Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci. 1997 Feb;145(2):205–11.

38. Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006 Jun;66(11):1717–20.

39. Schmahmann JD, Gardner R, MacMore J, Vangel MG. Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS. Mov Disord. 2009 Sep;24(12):1820–8.

40. Brandsma R, Lawerman TF, Kuiper MJ, Lunsing RJ, Burger H, Sival DA. Reliability and discriminant validity of ataxia rating scales in early onset ataxia. Dev Med Child Neurol. 2017 Oct;59(4):427–32.

41. Bürk K, Sival DA. Scales for the clinical evaluation of cerebellar disorders. In: Handbook of Clinical Neurology. 2018. p. 329–39.

42. Bürk K. Friedreich Ataxia: current status and future prospects. Cerebellum & ataxias. 2017 Dec 7;4(1):4.

43. Kearney M, Orrell RW, Fahey M, Brassington R, Pandolfo M. Pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev. 2016 Aug;(8):CD007791.

44. Puccio H, Anheim M, Tranchant C. Pathophysiogical and therapeutic progress in Friedreich ataxia. Rev Neurol (Paris). 2014 May;170(5):355–65.

45. Sival DA, Pouwels ME, Brederode A Van, Maurits NM, Verschuuren-Bemelmans CC, Brunt ER, et al. In children with Friedreich ataxia, muscle and ataxia parameters are associated. Dev Med Child Neurol. 2011 Jun;53(6):529–34.

46. Corben LA, Lynch D, Pandolfo M, Schulz JB, Delatycki MB. Consensus clinical management guidelines for Friedreich ataxia. Orphanet J Rare Dis. 2014 Dec 30;9(1):184.

47. Boltshauser E. Cerebellar imaging–an important signpost in paediatric neurology. Childs Nerv Syst. 2001 Apr;17(4–5):211–6.

48. Bosemani T, Orman G, Boltshauser E, Tekes A, Huisman TA, Poretti A. Congenital abnormalities of the posterior fossa. Radiographics. 2015;35(1):200–20.

49. Poretti A, Boltshauser E, Doherty D. Cerebellar hypoplasia: differential diagnosis and diagnostic approach. Am J Med Genet C, Semin Med Genet. 2014 Jun;166C(2):211–26.

50. Poretti A, Wolf NI, Boltshauser E. Differential Diagnosis of Cerebellar Atrophy in Childhood: An Update. Neuropediatrics. 2015 Dec;46(6):359–70.

51. Elbeshlawi I, AbdelBaki MS. Safety of Gadolinium Administration in Children. Pediatr Neurol. 2018 Sep;86:27–32.

52. Razek AAA, Castillo M. Magnetic Resonance Imaging of Malformations of Midbrain-Hindbrain. J Comput Assist Tomogr. 2016;40(1):14–25.

53. Correa GG, Amaral LF, Vedolin LM. Neuroimaging of Dandy-Walker malformation: new concepts. Top Magn Reson Imaging. 2011 Dec;22(6):303–12.

54. Bernardo S, Vinci V, Saldari M, Servadei F, Silvestri E, Giancotti A, et al. Dandy-Walker Malformation: is the ‘tail sign’ the key sign? Prenat Diagn. 2015 Dec;35(13):1358–64.

55. Synofzik M, Soehn AS, Gburek-Augustat J, Schicks J, Karle KN, Schüle R, et al. Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. Orphanet J Rare Dis. 2013 Jan;8(1):41.

56. Prodi E, Grisoli M, Panzeri M, Minati L, Fattori F, Erbetta A, et al. Supratentorial and pontine MRI abnormalities characterize recessive spastic ataxia of Charlevoix-Saguenay. A comprehensive study of an Italian series. Eur J Neurol. 2013 Jan;20(1):138–46.

57. Gazulla J, Vela AC, Marín MA, Pablo L, Santorelli FM, Benavente I, et al. Is the ataxia of Charlevoix–Saguenay a developmental disease? Med Hypotheses. 2011 Sep;77(3):347–52.

58. Doherty D, Millen KJ, Barkovich AJ. Midbrain and hindbrain malformations: Advances in clinical diagnosis, imaging, and genetics. Vol. 12, The Lancet Neurology. 2013. p. 381–93.

59. Steenweg ME, Vanderver A, Blaser S, Bizzi A, de Koning TJ, Mancini GMS, et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain. 2010 Oct;133(10):2971–82.

60. Cavalier L, Ouahchi K, Kayden HJ, Donato S Di, Reutenauer L, Mandel JL, et al. Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families. Am J Hum Genet. 1998 Feb;62(2):301–10.

61. Elkamil A, Johansen KK, Aasly J. Ataxia with vitamin e deficiency in norway. J Mov Disord. 2015 Jan;8(1):33–6.

62. Federico A. Ataxia with isolated vitamin E deficiency: a treatable neurologic disorder resembling Friedreich’s ataxia. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2004 Jul;25(3):119–21.

63. Gabsi S, Gouider-Khouja N, Belal S, Fki M, Kefi M, Turki I, et al. Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency. Eur J Neurol. 2001 Sep;8(5):477–81.

64. Mariotti C, Gellera C, Rimoldi M, Mineri R, Uziel G, Zorzi G, et al. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2004 Jul;25(3):130–7.

65. Schuelke M. Ataxia with Vitamin E Deficiency. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. Seattle (WA): University of Washington, Seattle; 1993. (GeneReviews(®)).

66. Zelante G, Patti F, Vinciguerra L, Gellera C, Zappia M. Ataxia with vitamin E deficiency caused by a new compound heterozygous mutation. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2016 Sep;37(9):1571–2.

67. Hammans SR, Kennedy CR. Ataxia with isolated vitamin E deficiency presenting as mutation negative Friedreich’s ataxia. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):368–70.

68. Chardon L, Sassolas A, Dingeon B, Michel-Calemard L, Bovier-Lapierre M, Moulin P, et al. Identification of two novel mutations and long-term follow-up in abetalipoproteinemia: a report of four cases. Eur J Pediatr. 2009 Aug;168(8):983–9.

69. Nagappa M, Bindu PS, Adwani S, Seshagiri SK, Saini J, Sinha S, et al. Clinical, hematological, and imaging observations in a 25-year-old woman with abetalipoproteinemia. Ann Indian Acad Neurol. 2014 Jan;17(1):113–6.

70. Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol. 2014 Jun;25(3):161–8.

71. Hentati F, El-Euch G, Bouhlal Y, Amouri R. Ataxia with vitamin E deficiency and abetalipoproteinemia. Handb Clin Neurol. 2012;103:295–305.

72. Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991 Apr;266(12):7779–83.

73. Federico A, Dotti MT. Cerebrotendinous xanthomatosis. Neurology. 2001 Nov;57(9):1743.

74. Keren Z, Falik-Zaccai TC. Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease. Pediatr Endocrinol Rev PER. 2009 Sep;7(1):6–11.

75. Patni N, Wilson DP. Cerebrotendinous Xanthomatosis. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. South Dartmouth (MA): MDText.com, Inc.; 2000. (Endotext).

76. Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, Pardo J, Arias M, Ares-Luque A, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol. 2011 Oct;18(10):1203–11.

77. Federico A, Dotti MT, Gallus GN. Cerebrotendinous Xanthomatosis. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. Seattle (WA): University of Washington, Seattle; 1993. (GeneReviews(®)).

78. Stefano N De, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain A J Neurol. 2001 Jan;124(Pt 1):121–31.

79. Vanrietvelde F, Lemmerling M, Mespreuve M, Crevits L, Reuck J De, Kunnen M. MRI of the brain in cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease). Eur Radiol. 2000;10(4):576–8.

80. Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P. Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis. 2008 Dec;31 Suppl 2:241.

81. van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr. 1998 Apr;157(4):313–6.

82. Liu W, Narayanan V. Ataxia with oculomotor apraxia. Semin Pediatr Neurol. 2008 Dec;15(4):216–20.

83. Coutinho P, Barbot C. Ataxia with Oculomotor Apraxia Type 1. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. Seattle (WA): University of Washington, Seattle; 1993. (GeneReviews(®)).

84. Ber I Le, Bouslam N, Rivaud-Péchoux S, Guimarães J, Benomar A, Chamayou C, et al. Frequency and phenotypic spectrum of ataxia with oculomotor apraxia 2: a clinical and genetic study in 18 patients. Brain A J Neurol. 2004 Apr;127(Pt 4):759–67.

85. Mhanni AA, Hartley JN, Harward E, Spriggs E, Booth F. Ataxia with oculomotor apraxia type 2 in the Canadian aboriginal population. Clin Genet. 2016 Apr;89(4):515–6.

86. Szpisjak L, Obal I, Engelhardt JI, Vecsei L, Klivenyi P. A novel SETX gene mutation producing ataxia with oculomotor apraxia type 2. Acta Neurol Belg. 2016 Sep;116(3):405–7.

87. Tazir M, Ali-Pacha L, M’Zahem A, Delaunoy JP, Fritsch M, Nouioua S, et al. Ataxia with oculomotor apraxia type 2: a clinical and genetic study of 19 patients. J Neurol Sci. 2009 Mar;278(1–2):77–81.

88. Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016 Nov;11(1):159.

89. Pearson TS. More Than Ataxia: Hyperkinetic Movement Disorders in Childhood Autosomal Recessive Ataxia Syndromes. Tremor Other Hyperkinet Mov (N Y). 2016;6:368.

90. Kwast O, Ignatowicz R. Progressive peripheral neuron degeneration in ataxia-telangiectasia: an electrophysiological study in children. Dev Med Child Neurol. 1990 Sep;32(9):800–7.

91. Stray-Pedersen A, Borresen-Dale AL, Paus E, Lindman CR, Burgers T, Abrahamsen TG. Alpha fetoprotein is increasing with age in ataxia-telangiectasia. Eur J Paediatr Neurol. 2007 Nov;11(6):375–80.

92. van de Warrenburg BPC, van Gaalen J, Boesch S, Burgunder J-M, Dürr A, Giunti P, et al. EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood. Eur J Neurol. 2014 Apr;21(4):552–62.

93. Theunissen TEJ, Nguyen M, Kamps R, Hendrickx AT, Sallevelt SCEH, Gottschalk RWH, et al. Whole exome sequencing is the preferred strategy to identify the genetic defect in patients with a probable or possible mitochondrial cause. Front Genet. 2018;

94. Ghaoui R, Sue CM. Movement disorders in mitochondrial disease. J Neurol. 2018 May 6;265(5):1230–40.

95. de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroes T, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012 Nov;367(20):1921–9.

96. van de Warrenburg B, Schouten M, De Bot S, Vermeer S, Meijer R, Pennings M, et al. Clinical exome sequencing for cerebellar ataxia and spastic paraplegia uncovers novel gene-disease associations and unanticipated rare disorders. Eur J Hum Genet. 2016 Oct;24(10):1460–6.

97. Salman MS, Sharpe JA, Lillakas L, Steinbach MJ. Square Wave Jerks in Children and Adolescents. Pediatr Neurol. 2008;